metadata toggle
Clinical particulars
Target species
Rabbits.
Indications for use
For active immunisation of rabbits from 5 weeks of age onwards to reduce mortality and clinical signs of myxomatosis and to prevent mortality due to rabbit haemorrhagic disease (RHD) caused by classical RHD virus strains.
Onset of immunity: 3 weeks.
Duration of immunity: 1 year.
Contra-indications
None.
Special warnings for each target species
None.
Special precautions for use
Special precautions for use in animals
Vaccinate only healthy rabbits.
Rabbits that have been vaccinated previously with another myxomatosis vaccine, or that have experienced natural myxomatosis infection in the field, may not develop a proper immune response against rabbit haemorrhagic disease following vaccination.
Operator warnings: None.
Adverse reaction
A transient temperature increase of 1 - 2 °C can commonly occur. A small, non-painful swelling (maximum 2 cm diameter) at the injection site is commonly observed within the first two weeks after vaccination. The swelling will resolve completely by 3 weeks after vaccination..
In pet rabbits, in very rare cases, local reactions at the injection site such as necrosis, scabs, crusts or hair loss may occur. In very rare cases serious hypersensitivity reactions, which may be fatal, may occur after vaccination. In very rare cases the appearance of mild clinical signs of myxomatosis may occur within 3 weeks of vaccination. Recent or latent infection with field myxoma virus seems to play a role in this to a certain extent.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).
Use during pregnancy, lactation or lay
Pregnancy:
Studies involving the use of the vaccine during early pregnancy were inconclusive, therefore vaccination is not recommended during the first 14 days of pregnancy.
Fertility:
No safety study on the reproductive performance has been conducted in male rabbits (bucks). Therefore, the vaccination of breeding bucks is not recommended.
Interactions
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Amounts to be administered and administration route
After reconstitution, administer 1 dose of vaccine by subcutaneous injection to rabbits from 5 weeks of age onwards.
Revaccinate annually.
Ensure that the lyophilisate is completely reconstituted before use.
Single dose vial Reconstitute a single dose vial of vaccine with 1 ml of Nobivac Myxo RHD solvent and inject the total contents of the vial.
Multi-dose vial
Solvent volume
Number of vials of freeze-dried vaccine to be added
Injection volume
Total number of rabbits that can be vaccinated
10 ml
1
0.2 ml
50
50 ml
5
0.2 ml
250
For proper reconstitution of the multidose vial, use the following procedure:
Add 1-2 ml of Nobivac Myxo RHD solvent to the 50 dose vaccine vial(s) and ensure that the lyophilisate is fully dissolved.
Withdraw the reconstituted vaccine concentrate from the vial(s) and inject it back into the Nobivac Myxo RHD solvent vial.
Ensure that the resulting vaccine suspension in the Nobivac Myxo RHD solvent vial is properly mixed.
Use the vaccine suspension within 4 hours of reconstitution. Any reconstituted vaccine remaining at the end of this time should be discarded.
Overdose
In addition to the adverse reactions observed after single dose vaccination, a mild swelling of the local lymph nodes may be observed within the first 3 days after overdose vaccination.
Withdrawal periods
Zero days.